BACKGROUND: Peptide YY (PYY) is a 36 amino-acid peptide secreted from ileal L cells following meals. The cleaved subpeptide PYY is biologically active and may constitute the majority of circulating PYY-like immunoreactivity. The peptide family that includes PYY, pancreatic peptide and neuropeptide Y is noted for its orexigenic effect following intracerebroventricular administration. OBJECTIVE: To investigate the effects of peripheral (intraperitoneal and chronic subcutaneous) infusions of PYY[3-36] on food intake, body weight and glycemic indices. DESIGN/RESULTS: Food intake was measured in normal mice and in several rodent models of obesity and type II diabetes. In marked contrast to the reported central orexigenic effects, in the present study, PYY acutely inhibited food intake by up to 45%, with an ED 50 of 12.5 mg/kg in fasted female NIH/Swiss mice. A 4-week infusion reduced weight gain in female ob/ob mice, without affecting the cumulative food intake. In diet-induced obese male mice, PYY[3-36] infusion reduced cumulative food intake, weight gain and epididymal fat weight (as a fraction of carcass) with similar ED 50 's (466, 297 and 201 mg/kg/day, respectively) and prevented a diet-induced increase in HbA1c. Infusion at 100 mg/kg/day for 8 weeks in male fa/fa rats reduced the weight gain (288711 vs 326712 g in saline-infused controls; Po0.05), similar to effects in a pair-fed group. In female ob/ob and db/db mice, there was no acute effect of PYY on plasma glucose concentrations. In male diabetic fatty Zucker rats, PYY infused for 4 weeks reduced HbA1c and fructosamine (ED 50 's 30 and 44 mg/kg/day). CONCLUSION: Peripheral PYY[3-36] administration reduced the food intake, body weight gain and glycemic indices in diverse rodent models of metabolic disease of both sexes. These findings justify further exploration of the potential physiologic and therapeutic roles of PYY .
Introduction
The pancreatic polypeptide family consists of pancreatic polypeptide (PP), secreted from pancreatic islets, neuropeptide Y (NPY) found in the brain and some peripheral nerves, especially those around blood vessels, and peptide YY (PYY), so named because it has a tyrosine (Y) at the N and C termini. PYY is secreted following meals 1,2 from intestinal L cells lining the terminal small bowel (the same cells that secrete GLP-1 and GLP-2). In addition, PYY is present in high concentrations in cells in the colon that do not produce GLP-1. At least six different pharmacologies (receptor types) for this ligand family have been identified and receptor names Y1-Y6 have been assigned. The subpeptide of PYY is cleaved under the action of dipeptidyl peptidase-IV (DPP4). This fragment, PYY , can constitute the majority of total PYY-like immunoreactivity after meals. 3, 4 PYY has been described as a selective ligand at the Y2 receptor type, which appears pharmacologically unique in preferring N-terminally truncated (ie, C-terminal fragments) NPY and PYY analogs. Much interest in this hormone family has been driven by reports of a marked increase in food intake (orexigenic effect) following intracerebroventricular injection of PP, NPY (especially the latter 5 ) and of PYY. 6, 7 Pharmaceutical efforts have focused on the development of antagonists that would cross the blood-brain barrier to block a tonic feeding response derived from endogenous orexigens. Of the multiple receptors that could mediate this orexigenic response, those most often implicated have been the Y5 and Y1 receptors. 8, 9 Against the backdrop of a central orexigenic effect, the finding in the present paper that peripheral administration of PYY decreased food intake was surprising. This result has been independently affirmed by Batterham et al in animals 10 and in humans. 10, 11 Our observations of a satiogenic effect, and a spectrum of gastrointestinal actions suggestive of a role in metabolic control, prompted investigation of the effects of PYY in rodent models of metabolic disease, and specifically in models of obesity and type II diabetes. In an effort to probe the robustness of our findings, we used both sexes, rats and mice, and both genetic and induced disease models in diverse protocols. Some of the findings reported here have been presented in abstract form.
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Research design and methods
Six sets of experiments were conducted in rodent models, comprising one set investigating the acute effects on food intake in normal mice, and five sets looking at chronic measures in rodent models of metabolic disease. The latter comprised three sets of experiments in obese models (genetically obese ob/ob mice, genetically obese fa/fa rats and diet-induced obese mice) and two sets in diabetic models (db/db þ ob/ob mice and ZDF rats).
Materials
PYY was synthesized at Amylin Pharmaceuticals, Inc by solid-phase chemistry, and was purified by HPLC (498% purity, 84% peptide content). It was characterized by aminoacid analysis and LC/MS. 
Chemical analyses
Experiments in nonobese models
Effect of acute administration of PYY 
Experiments in obese models
Effect of chronic infusion of PYY Effect of chronic infusion of PYY on food intake and body weight in high-fat (HF)-fed C57BL/6J (dietinduced obese) mice In total, 98 male C57BL/6 mice were acclimated for 1 week, housed four per cage and provided with food and water ad libitum, before entering the study at age 43 days (mean weight 19.3 g). Mice were then assigned to a low-fat (LF; 11% fat calories; D12329) or a HF (58% fat calories; D12331) diet, which was consumed throughout the treatment period (Research Diets, New Brunswick, NJ, USA). Following 4 weeks of diet treatment, Alzet s osmotic pumps (model 2004, 28-day delivery; Durect Corp, Cupertino, CA, USA) were loaded with phosphate-buffered saline (PBS) or with PYY dissolved in PBS, so as to deliver 30, 100, 300 and 1000 mg/kg/day. After overnight incubation at 371C in sterile PBS to initiate delivery, pumps were implanted subcutaneously between the scapulae in mice anesthetized with isoflurane. Wounds were closed with a single surgical staple that was removed after 7 days. Treatment groups were:
(1) LF-fed controls, with access to an 11% fat diet (n ¼ 22).
(2) HF-fed controls, with access to a 58% fat diet, infused with PBS (n ¼ 20). (3) Treated as per group 2, but infused with PYY at 30 mg/kg/day (n ¼ 14).
(4) Treated as per group 2, but infused with PYY at 100 mg/kg/day (n ¼ 14). (5) Treated as per group 2, but infused with PYY at 300 mg/kg/day (n ¼ 14). (6) Treated as per group 2, but infused with PYY at 1000 mg/kg/day (n ¼ 14).
Mice were housed two per cage for the next 28 days, during which food intake and body weight were measured. At 28 days, anesthetized mice were exsanguinated for measurement of HbA1c. As an index of adiposity, epididymal fat pads were excised, weighed and expressed as a fraction of eviscerated carcass weight.
Effect of chronic infusion of PYY on food intake and body weight in Fatty Zucker (fa/fa) rats Effects of PYY were tested in 20 male obese nondiabetic Zucker fatty (fa/fa) rats (Charles River Labs; age 52 days, mean weight 294 g). Animals were assigned into three weight-matched groups, comprising:
(1) PYY infused at 100 mg/kg/day by Alzet s pump (n ¼ 7).
(2) Pair-fed controls infused saline via pump, but fed the same quantity of food consumed by group (1) in the prior 24 h (n ¼ 7). (3) Saline-infused animals fed ad libitum (n ¼ 6).
Pumps were replaced after 4 weeks to give the total drug exposure for 8 weeks. Food consumption and body weight were measured daily, and fasting plasma glucose, fructosamine, cholesterol and triglycerides were measured weekly.
Experiments in diabetic models
Effects of acute administration of PYY on glycemia in db/db and ob/ob mice In all, 14 hyperglycemic female db/db mice (age 70 days, mean weight 42. 0 g) and 15 obese ob/ob female mice (age 68 days, mean weight 46.6 g) were fasted for 2 h before collection of a baseline retro-orbital blood sample for plasma glucose measurement under light anesthesia. Animals were then injected intraperitoneally with saline, 300 or 1000 mg/ kg PYY (n ¼ 5/dose) before further sampling 60 min later.
Effect of chronic continuous delivery of PYY on glycemia in diabetic fatty Zucker (ZDF) rats In all, 44 male Diabetic fatty Zucker rats (ZDF)/Gmit-(fa/fa) were obtained from Charles River at B6 weeks of age and acclimated for 1 week before measuring HbA1c in blood sampled from the topically anesthetized tail. Animals were then stratified according to HbA1c for distribution by this parameter into four HbA1c-matched treatment groups:
(1) Saline-infused control, n ¼ 14.
(2) PYY 30 mg/60 ml/day, n ¼ 10. (3) PYY 100 mg/60 ml/day, n ¼ 10. (4) PYY 300 mg/60 ml/day, n ¼ 10.
After HbA1c matching and a further week of acclimation, at age 59 days (mean weight 292 g), mini-osmotic pumps (Alzet s 2ML4) were implanted under halothane anesthesia for delivery of PYY or saline. Food intake, water intake and body weight were measured daily. Beginning at day 0 and continuing until day 28, blood was taken weekly for measurement of HbA1c and fructosamine.
After 28 days of treatment, subsets of rats (n ¼ 5, 5, 5, 4/ group) were subjected to a 3-h hyperinsulinemic euglycemic clamp. After an overnight fast, animals were anesthetized with isoflurane, tracheotomized and catheterized via the femoral artery and vein. The osmotic pump was removed (t ¼ À150 min) and the femoral artery infused with saline (1 ml/h) for fluid maintenance, to record the arterial pressure and for glucose measurements (YSI 2300 STAT analyzer). The femoral vein was used for infusion of recombinant human insulin (Humulin 
Statistical methods
For all sets of experiments, general effects were tested by oneway analysis of variance (ANOVA), with Dunnett's post test performed using GraphPad InStat version 3.05. for Windows 95, GraphPad Software, San Diego, CA, USA, www.graphpad.com. Pair-wise comparisons were performed using Student-Newman-Keul's test for significance at a ¼ 0.05. Dose-response curves were fitted to a four-parameter logistic function using nonlinear regression routines contained within Prism (v4.01, GraphPad Software, San Diego, CA, USA). Data are expressed as the means7s.e.m., unless otherwise stated.
Results
Experiments in nonobese models
Effect of acute administration of PYY on food intake in NIH/Swiss mice. Intraperitoneal injections of PYY dose-dependently reduced food intake over the next 60 min in fasted mice by up to 4573%. The ED 50 for this effect was PYY Figure 1 ).
Experiments in obese models
Effect of chronic infusion of PYY on food intake and body weight in ob/ob (B6.VLep ob ). mice. After 4 weeks of infusion, there was a dose-dependent effect on body weight, with the saline-infused animals gaining 3.471.3 g over the mean starting weight of 51.4 g. Following infusions of 100, 300 and 1000 mg/kg/day PYY , weight gains were reduced, respectively, to 1.971.6, 0.572.3 (Po0.001) and À0.772.9 g (ie, weight loss; Po0.002). There was no difference in the cumulative food intake over 4 weeks between the groups. Neither were there differences between groups in fasting plasma glucose, cholesterol, triglyceride and fructosamine concentrations after 4 weeks of treatment (data not shown). In summary, chronic PYY infusion in ob/ob mice was associated with a dose-dependent decrease in body weight compared to saline-infused animals. This effect appeared to be dissociated from effects on food intake and was not accompanied by changes in glycemic indices (see Figure 2) .
Effect of chronic infusion of PYY on food intake and body weight in HF-fed C57BL/6J (diet-induced obese) mice. HF feeding resulted in increased body mass (31.670.3 g. HF vs 25.070.5 g LF, mean7s.e.m.; Po0.0001) and increased adiposity, as measured by the ratio of epididymal fat weight/eviscerated carcass weight (6.370.3% HF vs 2.770.1% LF; Po0.01). Relative to the starting weight of 31.6 g, PYY infusion dose-dependently decreased body weight gain in HF mice (0.870.3 g at 1000 mg/kg/day dose vs 3.570.3 g in saline-infused HF controls; ANOVA Po0.0001) and decreased adiposity (4.970.4% vs 6.370.3%; Po0.05).
A HF diet increased HbA1c (3.9070.06% HF vs 3.7270.06% LF; Po0.05), an effect that was reversed with a 1000 mg/kg/day PYY infusion (3.6470.06%; Po0.01 vs HF saline-treated). The ED 50 's for dose-dependent effects of PYY infusion on food intake, weight gain, food efficiency and adiposity were similar. The ED 50 for the 120-kcal (17.9%) reduction in 28-day food intake was 466 mg/kg/ day70.14 log units. Reduction in body weight gain occurred with an ED 50 of 297 mg/kg/day70.07 log; the ED 50 for food efficiency (g gained per 100 kcal consumed) was 467 mg/kg/ day70.06 log; the ED 50 for reduction in adiposity (expressed as epididymal fat weight as a fraction of carcass weight) was 201 mg/kg/day70.44 log (see Figure 3) . PYY in obese and diabetic rodents RA Pittner et al
Effect of chronic infusion of PYY on food intake and body weight in Fatty Zucker (fa/fa) rats. After 8 weeks, body weight gain (mean7s.e.m.) in the PYY (288.4711.1 g) and pair-fed groups was similar (281.0710.7) and significantly lower than in saline-infused ad libitum-fed controls (326.0711.7; Po0.05). Cumulative food consumption (g) in the PYY (1799750, P ¼ 0.07) and pair-fed (1650740, Po0.001) groups was lower than in ad libitum-fed controls (1922733). There were no treatmentrelated changes in glucose, fructosamine, cholesterol or triglyceride values. These results, obtained in the absence of glycosuria, indicate an effect of PYY to decrease food consumption and body weight in obese nondiabetic fa/fa rats. These results contrast with those in diabetic fatty Zucker rats (presented below), in which absence of (or paradoxical) weight effects may have been related to reversal of glycosuria and reversal of caloric losses in the urine (see Figure 4) .
Experiments in diabetic models
Effects of acute administration of PYY on plasma glucose concentrations in db/db and ob/ob mice. In fasting ob/ob mice, baseline plasma glucose concentrations of 10.170. 8 mM were not significantly modified 60 min after intraperitoneal PYY injections of 300 or 1000 mg/kg (60-min changes À0.2470.41, 0.3470.78, 0.8170.73 mM for saline, 300, 1000 mg/kg doses, respectively). Similarly, there was no significant effect on basal plasma glucose concentrations of 11.871.3 mM 60 min after injection of PYY in db/db mice (respective 60-min changes 0.9071.56, 2.3171.35, 0.5170.51 mM). That is, there was no acute glucose-lowering effect of PYY in fasted ob/ob and db/db mouse models of hypernutrition.
Effect of chronic continuous delivery of PYY on glycemic indices in ZDF rats. PYY infusion for 4 weeks was associated with a dose-dependent reduction in cumulative food intake (740.0783.7,. 711.4777.3, 639.8752.9 and 624.2740.9 g for saline, 30, 100 and 300 mg/day groups, respectively; Po0.01 for two highest doses vs saline). However, changes in body weight were not dose dependent, and neither was there an association between changes in food consumption and changes in body weight from the initial mean weight of 291.8 g. PYY infusion dose-dependently reduced both glycemic measures, HbA1c and fructosamine. HbA1c vales were 5.871.7, 5.071.5, 4.771.4 and 4.270.9% for saline, 30, 100 and 300 mg/day groups, respectively (Po0.05 for the latter). The effect of PYY to reduce plasma fructosamine appeared similar in potency to the effect on HbA1c (Po0.05 for change in fructosamine at two highest doses) (see Figure 5) .
In a subset of rats (n ¼ 5, 5, 5, 4/group) subjected to euglycemic clamp after 28 days infusion, there was a trend towards a dose-dependent increase in insulin sensitivity, PYY in obese and diabetic rodents RA Pittner et al measured as the glucose infusion rate required to maintain euglycemia (681789, 634782, 7647110, 8387100 mg/kg for 60-180 min of clamp for saline, 30, 100 and 300 mg/day groups, respectively), but this trend was not statistically significant.
Discussion
Effects of PYY on food intake Peripherally injected PYY potently and dose-dependently inhibited 60-min food intake in overnight fasted nonobese mice. These results are supported by another report showing similar effects in fasted nonobese rats, mice 16 and in lean, normal and obese humans. 11, 16 Further, we
show here that PYY inhibited cumulative food intake in several animal models, including ob/ob mice, Fatty Zucker rats (diabetic and nondiabetic) and in diet-induced obese mice. This anorectic effect of peripheral PYY is in direct contrast to the appetite stimulation that has been reported with central administration of this molecule 9, 17 and of other related peptides, such as PYY 6, 7 and NPY. 5 The mechanism of this paradoxical anorectic effect of peripherally administered PYY is presently uncertain. Batterham et al 16 have proposed that PYY acts on presynaptic Y2 receptors on NPY neurons in the arcuate nucleus to reduce an orexigenic drive. Other experiments suggest that the area postrema may also be involved. For example, the area postrema is devoid of a blood-brain barrier, has been shown to bind circulating PYY 18 and is involved in control of food intake. 19 Lesions of area postrema attenuate the effects of PYY at the stomach. 20 Similarly, full-length PYY (PYY ) has been reported to bind to area postrema 21, 22 and to activate that region, as indicated by increases in c-fos expression. 23 Incidentally, effects of PYY on gastric motility, 24 Effects of PYY on body weight In a number of the obese rodent models tested in the present study, including ob/ob mice, diet-induced obese mice and nondiabetic Fatty Zucker rats, chronically administered PYY resulted in dose-dependent weight loss. Weight reduction was observed concomitantly with reduced caloric intake, so it is possible that weight effects were primarily driven by reductions in food intake.
However, in separate studies, we have noted a spectrum of gastrointestinal effects of PYY 20,30,31 that is similar to those described for full-length PYY (PYY ), which is reported to inhibit gastric emptying, [32] [33] [34] to inhibit secretion of gastric acid [35] [36] [37] [38] [39] and pancreatic enzymes 35, 40, 41 and to inhibit gallbladder emptying. 42 We have further noted the similarity between the spectrum of PYY actions just described, and that of amylin (which also inhibits food intake when administered peripherally). 43 The effect of the amylin analog, pramlintide, to promote weight loss and ameliorate glycemic indices in clinical studies [44] [45] [46] appears to be mediated via neuroendocrine control of nutrient appearance (Ra), some of which is attributable to gastrointestinal control of nutrient assimilation. 47 It is therefore possible that some of the effects of PYY on body weight are similarly associated with gastrointestinal control of nutrient assimilation. There are no effects of PYY on the endocrine pancreas (secretion of insulin, amylin or glucagon) that could account for its effect on body weight.
14 Effects of PYY on glycemia in diabetic models Here we report that, in hyperglycemic ob/ob and db/db mice, PYY had no acute effect on plasma glucose concentration, somewhat consistent with the absence of effect on nutrient-stimulated insulin or glucagon secretion. 14. We report here, however, that chronic (4-week) administration of PYY in ZDF rats resulted in a dose-dependent improvement in glycemic indices, including a reduction in HbA1c and fructosamine. This is the first indication that PYY has a glycemic benefit in a model of type II diabetes. The ZDF rat is a strain that develops not only insulin resistance, but also insulin secretory failure, and thence, frank hyperglycemia and glycosuria, and has been used as a model of human type II diabetes. 48 Paradoxically, in the present experiments, PYY did not cause weight loss, and at some doses enhanced body weight gain in this diabetic model. These effects were coincident with an amelioration of the diabetes, and urinary glucose measurements indicated that the preservation of body weight with PYY is likely to have been due to reversal of urinary caloric losses.
Summary
In summary, we describe the effects of peripherally administered PYY to decrease body weight in animal models of obesity, and to decrease glycemic indices in an animal model of type II diabetes. The mechanism, site of action, and pharmacology underlying these effects remains to be fully defined. However, the present results illuminate the possibility that PYY , or pharmaceutically suitable agonists, will have utility in the treatment of metabolic diseases such as diabetes and obesity.
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